Mesoblast share price rises after strong quarterly result

The Mesoblast Ltd (ASX: MSB) share price is an early mover after a strong first quarter update from the Aussie medical group.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price has already rocketed 4.83% in early trade after the company's first quarter results update this morning.

Why is the Mesoblast share price moving?

Mesoblast reported its operational highlights and financial results for the first quarter ended 30 September 2019.

The Aussie medical group saw 36% growth on the prior corresponding period (pcp) in group revenues to US$15.0 million. Mesoblast's TEMCELL revenues rocketed 85% higher on pcp in Japan in a boost for the company.

Mesoblast reported a 72% reduction in loss after tax compared to Q1 2019. This was driven by a 33% decrease in research and development expenditure as well as the increase in revenues.

The Mesoblast share price closed 0.56% higher at $1.80 per share yesterday but could climb higher in early trade.

What about operational highlights?

Mesoblast saw continued growth in its commercialisation revenues thanks largely to the Japanese market. The company's acute Graft Versus Host Disease (aGVHD) market adoption in Japan was strong and Mesoblast is hoping for the same in the United States.

The Mesoblast share price will be one to watch today following the broadly positive quarterly update on a financial and operational front.

Mesoblast entered into an agreement with Lonza in October 2019 for commercial product manufacture. The Aussie company is looking to facilitate appropriate inventory build ahead of its planned remestemcel-L launch in the United States.

Mesoblast also entered into a strategic partnership with Grunenthal during the quarter. Mesoblast will receive US$150 million in upfront and milestone payments prior to the MPC-06-ID product launch.

The companies are working together to develop and commercialise the product to treat lower back pain due to a degenerative disc disease.

According to Mesoblast, cumulative milestone payments could exceed US$1 billion depending on the outcome of its Phase 3 studies and patient adoption.

The company has an upcoming FDA filing for its remestemcel-L for aGVHD. If approved, Mesoblast expects to launch the product next year.

The Mesoblast share price is up 49.21% higher in 2019 and has a market cap just over $1 billion.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »